Ionis Pharmaceuticals, Inc.
Modulation of alpha synuclein expression

Last updated:

Abstract:

Disclosed herein are antisense compounds and methods for decreasing alpha-synuclein mRNA and protein expression. Also disclosed herein are methods for treating, preventing, and ameliorating neurodegenerative diseases in an individual in need thereof.

Status:
Grant
Type:

Utility

Filling date:

18 Apr 2017

Issue date:

27 Oct 2020